Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ATXI US Equity

Avenue Therapeutics, Inc.Health Care · Pharmaceutical Preparations · CIK 1644963 · FY ends Dec 31
$0.25
+0.00 (+0.00%)
USD · as of 2026-08-19 · marketstack
3 registered studies · 1 active

Studies where ATXI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

3 interventional · 2 with posted results

Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain AbdominoplastyNCT03774836The Sum of Pain Intensity Differences through 24 hoursRandomized · Triple-masked · TreatmentPhase 3Active, not recruitingDrug: Tramadol, Morphine · Other: PlaceboPain Management3602019-05-302019-05-09
Evaluate Safety of Tramadol in the Management of Postoperative Pain Following SurgeryNCT03395808results2021-03-09Adverse EventsOpen-label · OtherStudy Protocol · Statistical Analysis PlanPhase 3CompletedDrug: TramadolPain Management2512019-04-25actual2021-03-09
Tramadol Versus Placebo in the Management of Postoperative Pain Following BunionectomyNCT03290378results2020-03-19The Sum of Pain Intensity Differences (SPID) Through 48 Hours Post First DoseRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis PlanPhase 3CompletedDrug: Tramadol · Other: PlaceboPain Management4092018-04-11actual2020-03-19

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19